| Document |
Document Title |
|
WO/2021/216998A1 |
Disclosed herein, inter alia, are compounds, modified nucleotides, compositions, and methods of using the same.
|
|
WO/2021/216722A1 |
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/216940A1 |
A method of producing a triazoline-containing compound, the method comprising reacting an alkene, which comprises at least one a C=C double bond, with an azido compound, which comprises an azide anion having the chemical formula N3 -, wh...
|
|
WO/2021/214299A1 |
The present invention relates to Nicotinamide mononucleotide derivatives of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections. The present invention further relates to phar...
|
|
WO/2021/211890A1 |
In one aspect, the disclosure relates to pharmaceutical compositions comprising 2'-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates t...
|
|
WO/2021/211759A1 |
Disclosed herein are methods, compositions and kits for treating and inhibiting Poxviridae virus infections, for example, Vaccinia virus infections. Further disclosed are stop- gap methods for controlling the spread of Poxviridae virus i...
|
|
WO/2021/203409A1 |
A novel non-hygroscopic low-variability crystalline form for treatment of hepatitis C. The novel crystalline form T has a simple crystallization process, is easy for industrial production, and has no hygroscopicity. The use of a suitable...
|
|
WO/2021/196105A1 |
The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a ...
|
|
WO/2021/202907A2 |
The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remd...
|
|
WO/2021/202788A2 |
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard 4' -thio nucleoside.
|
|
WO/2021/198958A1 |
A nucleic acid polymer comprising 8 to 50 nucleoside subunits linked by intersubunit linkages, wherein the nucleic acid polymer comprises (A) one or more 3'-5' thiophosphoramidate intersubunit linkage and the remaining intersubunit linka...
|
|
WO/2021/196349A1 |
An organic acid salt of nicotinamide riboside; the organic acid is selected from malic acid, citric acid, royal jelly acid, and so on, and the molar ratio of nicotinamide riboside to organic acid is 1:2 or 1:1. A compound composition of ...
|
|
WO/2021/198883A1 |
Methods of synthesizing oligonucleotides via new intermediates on a cleavable support having an azidomethyl moiety are disclosed. The method comprises multiple reaction cycles, each of which comprises sequential coupling a nucleoside or ...
|
|
WO/2021/198040A1 |
The invention relates to a method for preparing 3'-O-amino-2'-deoxyribonucleoside- 5'-triphosphates with reduced 3'-hydroxy-2'-deoxyribonucleoside-5'-triphosphate contamination by converting 3'-(N-acetone-oxime)-2'-deoxynucleoside tripho...
|
|
WO/2021/198725A1 |
The invention relates to fosalvudine and fozivudine tidoxil for use in the treatment of the coronavirus disease 2019 and to the use of the structurally simplified derivatives thereof for manufacturing a drug against Covid-19.
|
|
WO/2021/191830A1 |
The present invention relates to methods and intermediates for the synthesis of nucleosides and nucleoside analogues (NAs). More specifically, the present invention relates to methods of synthesizing nucleosides and NAs, using simple ach...
|
|
WO/2021/191333A1 |
The present invention relates to a compound library comprising a plurality of conjugate molecules, wherein said conjugates comprise a small organic molecule covalently coupled to a nucleic acid moiety, wherein the nucleic acid moiety com...
|
|
WO/2021/192683A1 |
A compound comprising β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, wherein the purity measured by HPLC is 95% or higher, and the reactivity to lactate dehydrogenase is 30 U or higher.
|
|
WO/2021/189143A1 |
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its...
|
|
WO/2021/188959A1 |
The present disclosure provides prodrugs of 4'-C-substituted-2- halo-2'-deoxyadenoside nucleosides, and compositions, methods and kits thereof. Such compounds can be useful for treating viral infections including, human immunodeficiency ...
|
|
WO/2021/186328A1 |
Provided herein are novel synthetic routes to amines through an oxime intermediate, e.g., 3'-N nucleosides and novel and intermediate compounds produced during these synthetic procedures.
|
|
WO/2021/173615A1 |
Functionalized solid supports are useful in the synthesis of oligonucleotides. The functionalized solid supports contain an extended linker to a terminal functional group or a first nucleotide or nucleoside moiety. The extended linker pe...
|
|
WO/2021/173713A1 |
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 vi...
|
|
WO/2021/167029A1 |
Disclosed is a bridged nucleoside and a nucleotide using the same. The nucleoside according to the present invention is represented by formula (I). The bridged nucleoside of the present invention is usable as a substitute for a phosphoro...
|
|
WO/2021/162725A1 |
A composition that is a fullerene covalently bonded to a phosphate of adenosine with a +5 phosphorus oxidation state. The fullerene can be C60 fullerene or C70 fullerene. A first fullerene can covalently bonded to one functional group of...
|
|
WO/2021/159044A1 |
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.
|
|
WO/2021/155477A1 |
This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low...
|
|
WO/2021/146488A1 |
The present invention relates to nucleic acids and analogues thereof useful as potent and stable RNA interference agents.
|
|
WO/2021/140471A1 |
A method of making nucleoside 1, which has a 3-hydrocarbyl-5-fluoro-5-(hydroxy-methyl)tetrahydrofuran-3,4
-diol ring system, where hydrocarbyl group R1 is lower alkyl, lower alkenyl, or lower alkynyl and R2 may be an adenine moiety havin...
|
|
WO/2021/137913A2 |
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...
|
|
WO/2021/133859A1 |
Provided herein is a new molecular marker in DNA: N-4-acetyldeoxycytidine ("N4-acdC"). Also provided herein are methods of detecting N4-acdC residues in DNA molecules as well as methods of using detected N4-acdC residues, for example in ...
|
|
WO/2021/122719A1 |
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.
|
|
WO/2021/125819A1 |
A method for preparing uridine 5'-diphosphate (UDP), a salt thereof or a hydrate thereof, of the present invention, comprises the steps of: (step 1) deionizing a salt of uridine 5'-monophosphate (UMP) represented by chemical formula 2a w...
|
|
WO/2021/123074A1 |
The present disclosure provides a method for sequencing target polynucleotide molecules. In some embodiments, the present disclosure provides a method of sequencing by synthesis where different subsets of nucleotide-conjugate complexes a...
|
|
WO/2021/125708A1 |
The present invention relates to a nicotinamide riboside derivative conjugated to a fatty amine, and a composition comprising same, the composition being for wrinkle reduction, whitening, cell regeneration, hair-loss treatment, or anti-i...
|
|
WO/2021/104845A1 |
Embodiments of the present disclosure relate to cyclooctatetraene (COT) containing dyes and their uses as fluorescent labels. The fluorescent compounds comprise photo-protecting cyclooctatetraene moiety of formula (I). Also provided are ...
|
|
WO/2021/105916A1 |
The present invention relates to bispecific compound of formula (I) as dual inhibitors of CD73 and adenosine receptors. The present invention also relates to pharmaceutical compositions comprising said compounds or a pharmaceutically acc...
|
|
WO/2021/108291A1 |
The disclosure is directed to monomers and methods for synthesizing oligonucleotides comprising at least one nucleoside comprising a 3'-hydroxyl group.
|
|
WO/2021/106856A1 |
The purpose of the present invention is to provide a novel composition capable of improving urinary function, in particular a novel composition capable of improving urinary tract function and blood flow in the bladder. This composition...
|
|
WO/2021/098725A1 |
It relates to use of nicotinamide mononucleotide, in particular, relates to use of nicotinamide mononucleotide for the preparation of a medicament for preventing or alleviating liver injury or liver fibrosis in a subject, and a method fo...
|
|
WO/2021/098379A1 |
Provided are a phenylalanine-amidated nucleotide derivative, a preparation method therefor and an application thereof. In the present invention, a compound is formed by binding halogenated phenylalanine to an amino group of an amino-cont...
|
|
WO/2021/101475A1 |
The invention is a drug for anticancer and antiviral therapy, comprising a nucleoside analogue (7) comprising a furan ring irreversibly bound to the RNA/DNA synthesis chain by phosphodiester bonds and having SP3 hybridization, and folic ...
|
|
WO/2021/101469A1 |
The invention is a drug for anticancer and antiviral therapy comprising a nucleoside analogue comprising furan ring with SP3 hybridization irreversibly linked to the RNA/DNA synthesis chain by phosphodiester linkages. The synthesis metho...
|
|
WO/2021/092919A1 |
Disclosed are a nicotinamide mononucleotide intermediate and a method for synthesizing nicotinamide mononucleotide, and the present invention belongs to the field of chemical synthesis. Provided is a method for synthesizing a nicotinamid...
|
|
WO/2021/088901A1 |
Provided herein are the compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds are also provided.
|
|
WO/2021/087136A1 |
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
|
|
WO/2021/081881A1 |
The present invention provides a carbohydrate compound, the structure of which is as represented by formula X, wherein R1 and R2 are independently selected from a substituted amido group, a substituted triazolyl group, and a substituted ...
|
|
WO/2021/085509A1 |
A nucleoside derivative represented by formula (1) or a salt thereof. In the formula, R1 represents an alkoxy group, a hydrogen atom or a halogen atom; R2 and R4 may be the same as or different from each other and independently represent...
|
|
WO/2021/086816A1 |
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described an...
|
|
WO/2021/079617A1 |
The present invention provides: an amidite compound capable of improving the yield and purity of a polyoligonucleotide; a glycoside compound serving as an intermediate of the amidite compound; and a production method for a polynucleotide...
|
